Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis : Episode 3
Opinion
Video
Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis
Heidi Crayton, MD, and Maria Lopes, MD, discuss the limitations of using relapse rates as a critical endpoint in trials for patients with non-relapsing secondary progressive multiple sclerosis experiencing disease progression without relapse, explore methods to assess therapeutic benefit in this population, examine the relationship between cost of care and disease severity, and highlight the impact of decreased mobility and cognition on MS patients along with strategies for improvement.
- Relapse rates have traditionally been viewed as a critical endpoint for previous MS trials, which are not applicable in patients with non-relapsing secondary progressive multiple sclerosis with disease progression without relapse. How do you determine whether a patient is benefitting from therapy in this patient population?
- What is the relationship of costs of care and disease severity in patients with MS, and how do payers view the current costs of care for patients with MS?
- What is the impact of decreased mobility and cognition on patients with MS, and what are some strategies to help improve it?
Related Content
December 19th 2024
